Intercept to Present at Upcoming Investor Conferences

NEW YORK, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced management will be participating in the following upcoming investor conferences:

  • Dr. Mark Pruzanski, Chief Executive Officer, will present at the 2014 Deutsche Bank BioFEST at 1:05 p.m. ET on Tuesday, December 2, 2014 in Boston
  • Dr. Pruzanski will present at the Oppenheimer Annual Healthcare Conference at 2:45 p.m. ET on Wednesday, December 10, 2014 in New York

Information for the availability of live webcasts for these events will be posted on the Investors page of Intercept's website at Archived webcasts will be available on Intercept's website for approximately two weeks following each webcast event.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent chronic liver and intestinal diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), and primary sclerosing cholangitis (PSC). OCA has received Fast Track Designation in the United States and orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Several large, randomized, controlled trials of OCA in the treatment of chronic liver disease have been completed. These include Intercept's Phase 3 POISE trial for the treatment of patients with PBC and the FLINT trial for the treatment of patients with NASH. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma. For more information about Intercept, please visit the company's website at:

CONTACT: Barbara Duncan or Senthil Sundaram Intercept Pharmaceuticals 1-646-747-1000 Media inquiries: Investor inquiries:

Source:Intercept Pharmaceuticals, Inc.